Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2002 Jul;87(1):18–21. doi: 10.1136/adc.87.1.18

Should the new pneumococcal vaccine be used in high-risk children?

A Finn 1, R Booy 1, R Moxon 1, M Sharland 1, P Heath 1
PMCID: PMC1751156  PMID: 12089114

Full Text

The Full Text of this article is available as a PDF (91.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andiman W. A., Mezger J., Shapiro E. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. J Pediatr. 1994 Jun;124(6):846–852. doi: 10.1016/s0022-3476(05)83169-5. [DOI] [PubMed] [Google Scholar]
  2. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  3. Barnett E. D., Pelton S. I., Cabral H. J., Eavey R. D., Allen C., Cunningham M. J., McNamara E. R., Klein J. O. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis. 1999 Jul;29(1):191–192. doi: 10.1086/520151. [DOI] [PubMed] [Google Scholar]
  4. Bernstein L. J., Krieger B. Z., Novick B., Sicklick M. J., Rubinstein A. Bacterial infection in the acquired immunodeficiency syndrome of children. Pediatr Infect Dis. 1985 Sep-Oct;4(5):472–475. doi: 10.1097/00006454-198509000-00005. [DOI] [PubMed] [Google Scholar]
  5. Choo S., Finn A. New pneumococcal vaccines for children. Arch Dis Child. 2001 Apr;84(4):289–294. doi: 10.1136/adc.84.4.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Choo S., Seymour L., Morris R., Quataert S., Lockhart S., Cartwright K., Finn A. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J. 2000 Sep;19(9):854–862. doi: 10.1097/00006454-200009000-00009. [DOI] [PubMed] [Google Scholar]
  7. Dagan R., Fraser D. Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatr Infect Dis J. 2000 May;19(5 Suppl):S79–S88. doi: 10.1097/00006454-200005001-00012. [DOI] [PubMed] [Google Scholar]
  8. Dagan R., Melamed R., Muallem M., Piglansky L., Greenberg D., Abramson O., Mendelman P. M., Bohidar N., Yagupsky P. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis. 1996 Dec;174(6):1271–1278. doi: 10.1093/infdis/174.6.1271. [DOI] [PubMed] [Google Scholar]
  9. Farley J. J., King J. C., Jr, Nair P., Hines S. E., Tressler R. L., Vink P. E. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr. 1994 Jun;124(6):853–858. doi: 10.1016/s0022-3476(05)83170-1. [DOI] [PubMed] [Google Scholar]
  10. French N., Nakiyingi J., Carpenter L. M., Lugada E., Watera C., Moi K., Moore M., Antvelink D., Mulder D., Janoff E. N. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000 Jun 17;355(9221):2106–2111. doi: 10.1016/s0140-6736(00)02377-1. [DOI] [PubMed] [Google Scholar]
  11. King J. C., Jr, Vink P. E., Chang I., Kimura A., Parks M., Smilie M., Lichenstein R., Farley J. J. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine. 1998 Feb;16(4):361–365. doi: 10.1016/s0264-410x(97)80914-0. [DOI] [PubMed] [Google Scholar]
  12. King J. C., Jr, Vink P. E., Farley J. J., Parks M., Smilie M., Madore D., Lichenstein R., Malinoski F. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1996 Mar;15(3):192–196. doi: 10.1097/00006454-199603000-00003. [DOI] [PubMed] [Google Scholar]
  13. King J. C., Jr, Vink P. E., Farley J. J., Smilie M., Parks M., Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics. 1997 Apr;99(4):575–580. doi: 10.1542/peds.99.4.575. [DOI] [PubMed] [Google Scholar]
  14. Kroon F. P., van Dissel J. T., Ravensbergen E., Nibbering P. H., van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine. 2000 Nov 22;19(7-8):886–894. doi: 10.1016/s0264-410x(00)00232-2. [DOI] [PubMed] [Google Scholar]
  15. Levine O. S., Farley M., Harrison L. H., Lefkowitz L., McGeer A., Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. 1999 Mar;103(3):E28–E28. doi: 10.1542/peds.103.3.e28. [DOI] [PubMed] [Google Scholar]
  16. Madhi S. A., Petersen K., Madhi A., Wasas A., Klugman K. P. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J. 2000 Dec;19(12):1141–1147. doi: 10.1097/00006454-200012000-00004. [DOI] [PubMed] [Google Scholar]
  17. Mbelle N., Huebner R. E., Wasas A. D., Kimura A., Chang I., Klugman K. P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999 Oct;180(4):1171–1176. doi: 10.1086/315009. [DOI] [PubMed] [Google Scholar]
  18. McIntyre J., Conroy S., Avery A., Corns H., Choonara I. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child. 2000 Dec;83(6):498–501. doi: 10.1136/adc.83.6.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Miller E., Waight P., Efstratiou A., Brisson M., Johnson A., George R. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998. Acta Paediatr Suppl. 2000 Dec;89(435):11–16. doi: 10.1111/j.1651-2227.2000.tb00776.x. [DOI] [PubMed] [Google Scholar]
  20. Molrine D. C., Guinan E. C., Antin J. H., Parsons S. K., Weinstein H. J., Wheeler C., McGarigle C., Blanding P., Phillips N. R., Kinsella K. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996 Apr 1;87(7):3012–3018. [PubMed] [Google Scholar]
  21. Mufson M. A., Hughey D. F., Turner C. E., Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine. 1991 Jun;9(6):403–407. doi: 10.1016/0264-410x(91)90126-q. [DOI] [PubMed] [Google Scholar]
  22. O'Brien K. L., Swift A. J., Winkelstein J. A., Santosham M., Stover B., Luddy R., Gootenberg J. E., Nold J. T., Eskenazi A., Snader S. J. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics. 2000 Nov;106(5):965–972. doi: 10.1542/peds.106.5.965. [DOI] [PubMed] [Google Scholar]
  23. Overturf G. D. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis. 1999;14:191–218. [PubMed] [Google Scholar]
  24. Overturf G. D., Powars D., Baraff L. J. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child. 1977 Jul;131(7):784–787. doi: 10.1001/archpedi.1977.02120200066014. [DOI] [PubMed] [Google Scholar]
  25. Sleeman K., Knox K., George R., Miller E., Waight P., Griffiths D., Efstratiou A., Broughton K., Mayon-White R. T., Moxon E. R. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis. 2000 Dec 21;183(2):239–246. doi: 10.1086/317924. [DOI] [PubMed] [Google Scholar]
  26. Sorensen R. U., Leiva L. E., Giangrosso P. A., Butler B., Javier F. C., 3rd, Sacerdote D. M., Bradford N., Moore C. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J. 1998 Aug;17(8):685–691. doi: 10.1097/00006454-199808000-00005. [DOI] [PubMed] [Google Scholar]
  27. Takala A. K., Jero J., Kela E., Rönnberg P. R., Koskenniemi E., Eskola J. Risk factors for primary invasive pneumococcal disease among children in Finland. JAMA. 1995 Mar 15;273(11):859–864. [PubMed] [Google Scholar]
  28. Vernacchio L., Neufeld E. J., MacDonald K., Kurth S., Murakami S., Hohne C., King M., Molrine D. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr. 1998 Aug;133(2):275–278. doi: 10.1016/s0022-3476(98)70235-5. [DOI] [PubMed] [Google Scholar]
  29. Vernacchio L., Romero-Steiner S., Martinez J. E., MacDonald K., Barnard S., Pilishvili T., Carlone G. M., Ambrosino D. M., Molrine D. C. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis. 2000 Mar;181(3):1162–1166. doi: 10.1086/315307. [DOI] [PubMed] [Google Scholar]
  30. Zarkowsky H. S., Gallagher D., Gill F. M., Wang W. C., Falletta J. M., Lande W. M., Levy P. S., Verter J. I., Wethers D. Bacteremia in sickle hemoglobinopathies. J Pediatr. 1986 Oct;109(4):579–585. doi: 10.1016/s0022-3476(86)80216-5. [DOI] [PubMed] [Google Scholar]
  31. Zielen S., Bühring I., Strnad N., Reichenbach J., Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun. 2000 Mar;68(3):1435–1440. doi: 10.1128/iai.68.3.1435-1440.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES